At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
PLN-74809 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF
In Brief
A Phase 2 clinical trial evaluating PLN-74809 and Knottin tracer for Idiopathic Pulmonary Fibrosis. Completed, enrolled 9 participants across 1 site.
Detailed Summary
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
CollaboratorsStanford University
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartFeb 2020
Primary CompletionJun 2022
Study CompletionJul 2022
TodayJul 2026
First PostedAug 28, 2019
Enrollment StartFeb 13, 2020
Primary CompletionJun 27, 2022
Study CompletionJul 5, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.8 years ago
Interventions
PLN-74809drug
PLN-74809
Knottin tracerradiation
Radiotracer